Patents Assigned to Acceleron Pharma Inc.
-
Patent number: 11857599Abstract: In certain aspects, the disclosure provides compositions and methods for treating spinal muscular atrophy. For example, in some embodiments, the disclosure provides ALK4:ActRIIB antagonists that may be used to treat spinal muscular atrophy, particularly treating one or more complications of spinal muscular atrophy including, for example, increasing muscle mass muscle strength, and bone mineral density.Type: GrantFiled: April 2, 2018Date of Patent: January 2, 2024Assignee: Acceleron Pharma Inc.Inventors: Ravindra Kumar, Rajasekhar Naga Venkata Sai Suragani, Jia Li
-
Publication number: 20230398181Abstract: In certain aspects, the present disclosure relates to methods of treating chronic liver disease, portal hypertension, primary sclerosing cholangitis, and hepatopulmonary syndrome, particularly associated clinical complications such as, for example, pulmonary fibrosis and/or interstitial lung disease (ILD), methods comprising administering T?RII antagonists comprising a heterologous domain and a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides methods for treating one or more complications associated with chronic liver disease, including interstitial lung disease (ILD) and pulmonary fibrosis, with T?RII antagonists of the present disclosure.Type: ApplicationFiled: June 2, 2023Publication date: December 14, 2023Applicant: Acceleron Pharma Inc.Inventors: Rajasekhar Naga Venkata Sai Suragani, Patrick Andre
-
Publication number: 20230398182Abstract: In certain aspects, the present disclosure relates to methods of treating Hermansky-Pudlak Syndrome (HPS) using a T?RII antagonist. In part, the disclosure provides T?RII antagonists comprising a heterologous domain and a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides methods for treating one or more complications associated with HPS, including complications associated with fibrosis and/or the lung (e.g., pulmonary fibrosis, interstitial lung disease (ILD)).Type: ApplicationFiled: June 2, 2023Publication date: December 14, 2023Applicant: Acceleron Pharma Inc.Inventors: Rajasekhar Naga Venkata Sai Suragani, Patrick Andre
-
Patent number: 11827689Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.Type: GrantFiled: April 30, 2021Date of Patent: November 28, 2023Assignee: ACCELERON PHARMA INC.Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay, Gang Li, Yossi Dagon, John Knopf
-
Patent number: 11807673Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.Type: GrantFiled: October 6, 2020Date of Patent: November 7, 2023Assignee: Acceleron Pharma Inc.Inventors: Ravindra Kumar, Rajasekhar Naga Venkata Sai Suragani, John Knopf
-
Publication number: 20230234998Abstract: In certain aspects, the present invention provides compositions and methods for altering iron metabolism to increase red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.Type: ApplicationFiled: February 27, 2023Publication date: July 27, 2023Applicant: ACCELERON PHARMA INC.Inventors: RAJASEKHAR NAGA VENKATA SAI SURAGANI, ASYA GRINBERG, DIANNE SAKO
-
Patent number: 11708414Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.Type: GrantFiled: June 17, 2021Date of Patent: July 25, 2023Assignee: Acceleron Pharma Inc.Inventors: John Knopf, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Asya Grinberg, Dianne Sako, Roselyne Castonguay, Yossi Dagon
-
Patent number: 11642394Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.Type: GrantFiled: February 28, 2020Date of Patent: May 9, 2023Assignee: ACCELERON PHARMA INC.Inventors: Ravindra Kumar, Rajasekhar Naga Venkata Sai Suragani
-
Patent number: 11622992Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.Type: GrantFiled: March 25, 2020Date of Patent: April 11, 2023Assignee: ACCELERON PHARMA INC.Inventors: Ravindra Kumar, John Knopf
-
Patent number: 11590201Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to treat fibrotic disorders.Type: GrantFiled: September 5, 2019Date of Patent: February 28, 2023Assignee: ACCELERON PHARMA, INC.Inventors: Asya Grinberg, Roselyne Castonguay, Eric Werner, Ravindra Kumar
-
Patent number: 11524990Abstract: Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.Type: GrantFiled: April 10, 2019Date of Patent: December 13, 2022Assignee: ACCELERON PHARMA INC.Inventors: Matthew L. Sherman, Kenneth M. Attie
-
Patent number: 11497794Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.Type: GrantFiled: June 4, 2021Date of Patent: November 15, 2022Assignee: ACCELERON PHARMA INC.Inventors: Ravindra Kumar, John Knopf
-
Patent number: 11497792Abstract: The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use.Type: GrantFiled: July 30, 2020Date of Patent: November 15, 2022Assignee: ACCELERON PHARMA INC.Inventors: Ravindra Kumar, Asya Grinberg
-
Patent number: 11471510Abstract: Provided herein are methods for the treatment in a subject of anemia, anemia requiring RBC transfusion, low or intermediate-1-risk myelodysplastic syndromes (MDS), and/or non-proliferative chronic myelomonocytic leukemia (CMML) in any mammals wherein the methods comprise administration of Activin-ActRII signaling inhibitors to a subject in need of the treatment.Type: GrantFiled: December 3, 2015Date of Patent: October 18, 2022Assignees: CELGENE CORPORATION, ACCELERON PHARMA INC.Inventors: Kenneth M. Attie, Christopher Rovaldi, Abderrahmane Laadem
-
Publication number: 20220296708Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.Type: ApplicationFiled: December 9, 2021Publication date: September 22, 2022Applicant: Acceleron Pharma Inc.Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra
-
Patent number: 11440949Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK.6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells.Type: GrantFiled: October 5, 2017Date of Patent: September 13, 2022Assignee: ACCELERON PHARMA INC.Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay
-
Patent number: 11318188Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.Type: GrantFiled: June 4, 2021Date of Patent: May 3, 2022Assignee: ACCELERON PHARMA INC.Inventors: Ravindra Kumar, John Knopf
-
Patent number: 11279746Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.Type: GrantFiled: February 27, 2020Date of Patent: March 22, 2022Assignee: ACCELERON PHARMA INC.Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
-
Patent number: 11267865Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of red blood cells or a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.Type: GrantFiled: October 5, 2017Date of Patent: March 8, 2022Assignee: ACCELERON PHARMA INC.Inventors: Ravindra Kumar, Asya Grinberg, Erik M. Vogan
-
Patent number: 11260107Abstract: The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia). In some embodiments, the compositions of the disclosure may be used to treat or prevent ulcers associated with anemia.Type: GrantFiled: October 18, 2019Date of Patent: March 1, 2022Assignee: ACCELERON PHARMA INC.Inventor: Kenneth M. Attie